Characterization of CD8+ T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)

Treatment of melanoma patients with mRNA electroporated dendritic cells (TriMixDC-MEL) stimulates T-cell responses against the presented tumor-associated antigens (TAAs). In the current clinical trials, melanoma patients with systemic metastases are treated, requiring priming and/or expansion of preexisting TAA-specific T cells that are able to migrate to both the skin and internal organs. We monitored the presence of TAA-specific CD8+ T cells infiltrating the skin at sites of intradermal TriMixDC-MEL injection (SKILs) and within the circulation of melanoma patients treated in two clinical trials. In 10 out of fourteen (71%) patients screened, CD8+ T cells recognizing any of the four TAA presented by TriMixDC-MEL cellular vaccine were found in both compartments. In total, 30 TAA-specific T-cell responses were detected among the SKILs and 29 among peripheral blood T cells, of which 24 in common. A detailed characterization of the antigen specificity of CD8+ T-cell populations in four patients indicates that the majority of the epitopes detected were only recognized by CD8+ T cells derived from either skin biopsies or peripheral blood, indicating that some compartmentalization occurs after TriMix-DC therapy. To conclude, functional TAA-specific CD8+ T cells distribute both to the skin and peripheral blood of patients after TriMixDC-MEL therapy.

[1]  Bart O. Roep,et al.  Simultaneous Detection of Circulating Autoreactive CD8+ T-Cells Specific for Different Islet Cell–Associated Epitopes Using Combinatorial MHC Multimers , 2010, Diabetes.

[2]  B. Neyns,et al.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  B. Neyns,et al.  Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. , 2012, Journal of immunological methods.

[4]  G. Gaudernack,et al.  Vaccination of patients with cutaneous melanoma with telomerase-specific peptides , 2011, Cancer Immunology, Immunotherapy.

[5]  C. Figdor,et al.  Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Drijfhout,et al.  T-Cell Immune Function in Tumor, Skin, and Peripheral Blood of Advanced Stage Melanoma Patients: Implications for Immunotherapy , 2011, Clinical Cancer Research.

[7]  H. Goossens,et al.  Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination , 2010, Proceedings of the National Academy of Sciences.

[8]  B. Neyns,et al.  Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma , 2011, Journal of immunotherapy.

[9]  V. Engelhard,et al.  Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control , 2003, The Journal of experimental medicine.

[10]  C. Figdor,et al.  Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Neyns,et al.  Immunotherapy of cancer with dendritic cells loaded with tumor antigens and activated through mRNA electroporation. , 2010, Methods in molecular biology.

[12]  S. Aamdal,et al.  Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer , 2006, Cancer Immunology, Immunotherapy.

[13]  B. Neyns,et al.  Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients , 2009, Clinical Cancer Research.

[14]  Ton N Schumacher,et al.  Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers , 2012, Nature Protocols.

[15]  V. Engelhard,et al.  Strategies and challenges in eliciting immunity to melanoma , 2008, Immunological reviews.

[16]  C. Heirman,et al.  Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. , 2012, Cancer research.

[17]  B. Neyns,et al.  Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient , 2012, Cancer Immunology, Immunotherapy.

[18]  Ton N. Schumacher,et al.  MHC-based detection of antigen-specific CD8+ T cell responses , 2010, Cancer Immunology, Immunotherapy.

[19]  C. Figdor,et al.  Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used , 2010, Cancer Immunology, Immunotherapy.

[20]  B. Neyns,et al.  Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  V. Engelhard,et al.  CD8 T Cells Activated in Distinct Lymphoid Organs Differentially Express Adhesion Proteins and Coexpress Multiple Chemokine Receptors , 2010, The Journal of Immunology.